<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(4)</volume><submitter>Maier IL</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Stroke-induced immunodepression is a well characterized complication of acute ischemic stroke. In experimental studies beta-blocker therapy reversed stroke-induced immunodepression, reduced infection rates and mortality. Recent, heterogeneous studies in stroke patients could not provide evidence of a protective effect of beta-blocker therapy. Aim of this study is to investigate the potential preventive effect of beta-blockers in subgroups of patients at high risk for stroke-induced immunodepression.&lt;h4>Methods&lt;/h4>Data from a prospectively derived registry of major stroke patients receiving endovascular therapy between 2011-2017 in a tertiary stroke center (University Medical Center Göttingen. Germany) was used. The effect of beta-blocker therapy on pneumonia, urinary tract infection, sepsis and mortality was assessed using multivariate logistic regression analysis.&lt;h4>Results&lt;/h4>Three hundred six patients with a mean age of 72 ± 13 years and a median NIHSS of 16 (IQR 10.75-20) were included. 158 patients (51.6%) had pre-stroke- and continued beta-blocker therapy. Beta-blocker therapy did not reduce the incidence of pneumonia (OR 0.78, 95% CI 0.31-1.92, p = 0.584), urinary tract infections (OR 1.51, 0.88-2.60, p = 0.135), sepsis (OR 0.57, 0.18-1.80, p = 0.334) or mortality (OR 0.59, 0.16-2.17, p = 0.429). Strokes involving the insula and anterio-medial cortex increased the risk for pneumonia (OR 4.55, 2.41-8.56, p&lt;0.001) and sepsis (OR 4.13, 1.81-9.43, p = 0.001), while right hemispheric strokes increased the risk for pneumonia (OR 1.60, 0.92-2.77, p = 0.096). There was a non-significantly increased risk for urinary tract infections in patients with beta-blocker therapy and insula/anterio-medial cortex strokes (OR 3.12, 95% CI 0.88-11.05, p = 0.077) with no effect of beta-blocker therapy on pneumonia, sepsis or mortality in both subgroups.&lt;h4>Conclusions&lt;/h4>In major ischemic stroke patients, beta-blocker therapy did not lower post-stroke infection rates and was associated with urinary tract infections in a subgroup with insula/anterio-medial strokes.</pubmed_abstract><journal>PloS one</journal><pagination>e0196174</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5919008</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Influence of beta-blocker therapy on the risk of infections and death in patients at high risk for stroke induced immunodepression.</pubmed_title><pmcid>PMC5919008</pmcid><pubmed_authors>Behme D</pubmed_authors><pubmed_authors>Liman J</pubmed_authors><pubmed_authors>Maier IL</pubmed_authors><pubmed_authors>Leyhe JR</pubmed_authors><pubmed_authors>Psychogios MN</pubmed_authors><pubmed_authors>Becker JC</pubmed_authors><pubmed_authors>Schnieder M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Influence of beta-blocker therapy on the risk of infections and death in patients at high risk for stroke induced immunodepression.</name><description>&lt;h4>Background&lt;/h4>Stroke-induced immunodepression is a well characterized complication of acute ischemic stroke. In experimental studies beta-blocker therapy reversed stroke-induced immunodepression, reduced infection rates and mortality. Recent, heterogeneous studies in stroke patients could not provide evidence of a protective effect of beta-blocker therapy. Aim of this study is to investigate the potential preventive effect of beta-blockers in subgroups of patients at high risk for stroke-induced immunodepression.&lt;h4>Methods&lt;/h4>Data from a prospectively derived registry of major stroke patients receiving endovascular therapy between 2011-2017 in a tertiary stroke center (University Medical Center Göttingen. Germany) was used. The effect of beta-blocker therapy on pneumonia, urinary tract infection, sepsis and mortality was assessed using multivariate logistic regression analysis.&lt;h4>Results&lt;/h4>Three hundred six patients with a mean age of 72 ± 13 years and a median NIHSS of 16 (IQR 10.75-20) were included. 158 patients (51.6%) had pre-stroke- and continued beta-blocker therapy. Beta-blocker therapy did not reduce the incidence of pneumonia (OR 0.78, 95% CI 0.31-1.92, p = 0.584), urinary tract infections (OR 1.51, 0.88-2.60, p = 0.135), sepsis (OR 0.57, 0.18-1.80, p = 0.334) or mortality (OR 0.59, 0.16-2.17, p = 0.429). Strokes involving the insula and anterio-medial cortex increased the risk for pneumonia (OR 4.55, 2.41-8.56, p&lt;0.001) and sepsis (OR 4.13, 1.81-9.43, p = 0.001), while right hemispheric strokes increased the risk for pneumonia (OR 1.60, 0.92-2.77, p = 0.096). There was a non-significantly increased risk for urinary tract infections in patients with beta-blocker therapy and insula/anterio-medial cortex strokes (OR 3.12, 95% CI 0.88-11.05, p = 0.077) with no effect of beta-blocker therapy on pneumonia, sepsis or mortality in both subgroups.&lt;h4>Conclusions&lt;/h4>In major ischemic stroke patients, beta-blocker therapy did not lower post-stroke infection rates and was associated with urinary tract infections in a subgroup with insula/anterio-medial strokes.</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018</publication><modification>2024-11-10T00:20:32.762Z</modification><creation>2019-03-26T23:34:25Z</creation></dates><accession>S-EPMC5919008</accession><cross_references><pubmed>29694433</pubmed><doi>10.1371/journal.pone.0196174</doi></cross_references></HashMap>